569 related articles for article (PubMed ID: 21486975)
21. Immunogenicity of 2-Dose HPV Vaccine Series for Postpartum Women: An Open-Label, Nonrandomized, Noninferiority Trial.
Moss CF; Wang R; Sao S; Chou B; Perin J; Lander ME; Thaker SM; Mann M; Coleman JS
JAMA Netw Open; 2024 Jan; 7(1):e2352996. PubMed ID: 38285445
[TBL] [Abstract][Full Text] [Related]
22. Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine.
Garland SM; Cheung TH; McNeill S; Petersen LK; Romaguera J; Vazquez-Narvaez J; Bautista O; Shields C; Vuocolo S; Luxembourg A
Vaccine; 2015 Nov; 33(48):6855-64. PubMed ID: 26411885
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - A randomized clinical trial.
Gilca V; Sauvageau C; Panicker G; De Serres G; Ouakki M; Unger ER
Vaccine; 2018 Nov; 36(46):7017-7024. PubMed ID: 30314913
[TBL] [Abstract][Full Text] [Related]
24. A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls.
Vesikari T; Brodszki N; van Damme P; Diez-Domingo J; Icardi G; Petersen LK; Tran C; Thomas S; Luxembourg A; Baudin M
Pediatr Infect Dis J; 2015 Sep; 34(9):992-8. PubMed ID: 26090572
[TBL] [Abstract][Full Text] [Related]
25. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A
Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity and safety of the human papillomavirus vaccine in young survivors of cancer in the USA: a single-arm, open-label, phase 2, non-inferiority trial.
Landier W; Bhatia S; Wong FL; York JM; Flynn JS; Henneberg HM; Singh P; Adams K; Wasilewski-Masker K; Cherven B; Jasty-Rao R; Leonard M; Connelly JA; Armenian SH; Robison LL; Giuliano AR; Hudson MM; Klosky JL
Lancet Child Adolesc Health; 2022 Jan; 6(1):38-48. PubMed ID: 34767765
[TBL] [Abstract][Full Text] [Related]
27. Long term follow up of persistence of immunity following quadrivalent Human Papillomavirus (HPV) vaccine in immunocompromised children.
MacIntyre CR; Shaw PJ; Mackie FE; Boros C; Marshall H; Seale H; Kennedy SE; Moa A; Chughtai AA; Trent M; O'Loughlin EV; Stormon M
Vaccine; 2019 Sep; 37(37):5630-5636. PubMed ID: 31402238
[TBL] [Abstract][Full Text] [Related]
28. Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study.
Romanowski B; Schwarz TF; Ferguson L; Peters K; Dionne M; Behre U; Schulze K; Hillemanns P; Suryakiran P; Thomas F; Struyf F
Hum Vaccin Immunother; 2016; 12(1):20-9. PubMed ID: 26176261
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trial.
Wu T; Hu YM; Li J; Chu K; Huang SJ; Zhao H; Wang ZZ; Yang CL; Jiang HM; Wang YJ; Lin ZJ; Pan HR; Sheng W; Wei FX; Li SW; Wang Y; Zhu FC; Li CG; Zhang J; Xia NS
Vaccine; 2015 Jul; 33(32):3940-6. PubMed ID: 26100924
[TBL] [Abstract][Full Text] [Related]
30. Randomized trial: immunogenicity and safety of coadministered human papillomavirus-16/18 AS04-adjuvanted vaccine and combined hepatitis A and B vaccine in girls.
Pedersen C; Breindahl M; Aggarwal N; Berglund J; Oroszlán G; Silfverdal SA; Szüts P; O'Mahony M; David MP; Dobbelaere K; Dubin G; Descamps D
J Adolesc Health; 2012 Jan; 50(1):38-46. PubMed ID: 22188832
[TBL] [Abstract][Full Text] [Related]
31. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial.
Huh WK; Joura EA; Giuliano AR; Iversen OE; de Andrade RP; Ault KA; Bartholomew D; Cestero RM; Fedrizzi EN; Hirschberg AL; Mayrand MH; Ruiz-Sternberg AM; Stapleton JT; Wiley DJ; Ferenczy A; Kurman R; Ronnett BM; Stoler MH; Cuzick J; Garland SM; Kjaer SK; Bautista OM; Haupt R; Moeller E; Ritter M; Roberts CC; Shields C; Luxembourg A
Lancet; 2017 Nov; 390(10108):2143-2159. PubMed ID: 28886907
[TBL] [Abstract][Full Text] [Related]
32. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
Van Damme P; Leroux-Roels G; Simon P; Foidart JM; Donders G; Hoppenbrouwers K; Levin M; Tibaldi F; Poncelet S; Moris P; Dessy F; Giannini SL; Descamps D; Dubin G
Vaccine; 2014 Jun; 32(29):3694-705. PubMed ID: 24674663
[TBL] [Abstract][Full Text] [Related]
33. Persistence of Immunity When Using Different Human Papillomavirus Vaccination Schedules and Booster-Dose Effects 5 Years After Primary Vaccination.
Lazcano-Ponce E; Torres-Ibarra L; Cruz-Valdez A; Salmerón J; Barrientos-Gutiérrez T; Prado-Galbarro J; Stanley M; Muñoz N; Herrero R; Hernández-Ávila M
J Infect Dis; 2019 Jan; 219(1):41-49. PubMed ID: 30085139
[TBL] [Abstract][Full Text] [Related]
34. Randomized controlled trial of two dosing schedules for human papillomavirus vaccination among college age males.
Lin CJ; Zimmerman RK; Nowalk MP; Huang HH; Raviotta JM
Vaccine; 2014 Feb; 32(6):693-9. PubMed ID: 24342252
[TBL] [Abstract][Full Text] [Related]
35. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study.
Denny L; Hendricks B; Gordon C; Thomas F; Hezareh M; Dobbelaere K; Durand C; Hervé C; Descamps D
Vaccine; 2013 Nov; 31(48):5745-53. PubMed ID: 24091311
[TBL] [Abstract][Full Text] [Related]
36. Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study.
Sankaranarayanan R; Joshi S; Muwonge R; Esmy PO; Basu P; Prabhu P; Bhatla N; Nene BM; Shaw J; Poli URR; Verma Y; Zomawia E; Pimple S; Tommasino M; Pawlita M; Gheit T; Waterboer T; Sehr P; Pillai MR;
Vaccine; 2018 Aug; 36(32 Pt A):4783-4791. PubMed ID: 29551226
[TBL] [Abstract][Full Text] [Related]
37. Co-administration of human papillomavirus-16/18 AS04-adjuvanted vaccine with hepatitis B vaccine: randomized study in healthy girls.
Schmeink CE; Bekkers RL; Josefsson A; Richardus JH; Berndtsson Blom K; David MP; Dobbelaere K; Descamps D
Vaccine; 2011 Nov; 29(49):9276-83. PubMed ID: 21856349
[TBL] [Abstract][Full Text] [Related]
38. Safety and immunogenicity of Innovax bivalent human papillomavirus vaccine in girls 9-14 years of age: Interim analysis from a phase 3 clinical trial.
Zaman K; Schuind AE; Adjei S; Antony K; Aponte JJ; Buabeng PB; Qadri F; Kemp TJ; Hossain L; Pinto LA; Sukraw K; Bhat N; Agbenyega T
Vaccine; 2024 Apr; 42(9):2290-2298. PubMed ID: 38431444
[TBL] [Abstract][Full Text] [Related]
39. Reduced dose human papillomavirus vaccination: an update of the current state-of-the-art.
Toh ZQ; Licciardi PV; Fong J; Garland SM; Tabrizi SN; Russell FM; Mulholland EK
Vaccine; 2015 Sep; 33(39):5042-50. PubMed ID: 26271829
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial.
Poland GA; Jacobson RM; Koutsky LA; Tamms GM; Railkar R; Smith JF; Bryan JT; Cavanaugh PF; Jansen KU; Barr E
Mayo Clin Proc; 2005 May; 80(5):601-10. PubMed ID: 15887427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
